Because of an increasing number of reports of adverse reactions associated with pharmaceutical excipients, in 1985 the Committee on Drugs issued a position statement1 recommending that the Food and Drug Administration mandate labeling of over-the-counter and prescription formulations to include a qualitative list of inactive ingredients. However, labeling of inactive ingredients remains voluntary. Adverse reactions continue to be reported, although some are no longer considered clinically significant, and other new reactions have emerged. The original statement, therefore, has been updated and its information expanded.
Skip Nav Destination
American Academy of Pediatrics| February 01 1997
- Views Icon Views
- Share Icon Share
- Search Site
Committee on Drugs; “Inactive” Ingredients in Pharmaceutical Products: Update (Subject Review). Pediatrics February 1997; 99 (2): 268–278. 10.1542/peds.99.2.268
Download citation file: